Drugs / A-FLU-v
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02962908 | Aug 2016 → Jul 2017 | influenza | PepTcell Limited | Completed | Mixed |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A-FLU-v | “0.5-mL subcutaneous injection of 500 µg of adjuvanted (1 dose) or nonadjuvanted (2 doses) FLU-v (A-FLU-v or NA-FLU-v) or adjuvanted or nonadjuvanted placebo (A-placebo or...” PMID 32150750 ↗ Mar 2020 |
| Known as | FLU-v | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02962908 ↗ |
| Known as | NA-FLU-v | “0.5-mL subcutaneous injection of 500 µg of adjuvanted (1 dose) or nonadjuvanted (2 doses) FLU-v (A-FLU-v or NA-FLU-v) or adjuvanted or nonadjuvanted placebo (A-placebo or...” PMID 32150750 ↗ Mar 2020 |
| Modality | Vaccine | “FLU-v is a vaccine that aims to protect against a wide range of flu viruses.” NCT02962908 ↗ |
| Route | Subcutaneous | “Each administration will be given subcutaneously.” NCT02962908 ↗ |